medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2020, Number 1

<< Back Next >>

Rev Nefrol Dial Traspl 2020; 40 (1)

Systemic vasculature in chronic kidney disease. Second part

Inserra F, Lavenia G, Forcada P, Castellaro BC

Language: Spanish
References: 67
Page: 62-75
PDF size: 450.54 Kb.


ABSTRACT

There exist significant structural changes in the artery wall in almost all clinical stages of chronic kidney disease. They constitute a prognostic marker and, at the same time, a progression factor and an event factor, both cardiovascular and renal. For that reason, it is essential to have an estimation of vascular damage and, even better, an accurate diagnosis.
Vascular evaluation during clinical consultation by means of determining pulse pressure and ankle-brachial pressure index are a helpful initial orientation of these patient´s artery damage. Today we can assess, in an accessible way, the structural lesions of the arteries by means of quantification and characterization, through vascular ultrasound, of carotid and femoral atherosclerotic plaques and through the pulse wave velocity. The vast majority of renal patients show increased pulse wave velocity, compared to healthy populations, as a result of multiple pathogenic mechanisms. Vascular alterations, both of large arteries and at the microcirculation level, are strongly linked to the progression of chronic kidney disease, as well as renal, cardiac and cerebral complications and events.
In individuals at risk of developing chronic kidney disease, or in those who already suffer from it, the measurement of arterial stiffness and of atherosclerotic damage to the vascular wall is a central parameter for evaluation and one of the objectives to consider when designing preventive strategies against deterioration of target organs and events.


REFERENCES

  1. Mitchell GF. Increased aortic stiffness: an unfavorablecardiorenal connection. Hypertension. 2004;43(2):151-3.

  2. Safar ME, London GM, Plante GE. Arterial stiffnessand kidney function. Hypertension. 2004;43(2):163-8.

  3. Mitchell GF, Hwang SJ, Vasan RS, Larson MG,Pencina MJ, Hamburg NM, et al. Arterial stiffness andcardiovascular events: the Framingham Heart Study.Circulation. 2010;121(4):505-11.

  4. Ohno Y, Kanno Y, Takenaka T. Central bloodpressure and chronic kidney disease. World J Nephrol.2016;5(1):90-100.

  5. Townsend RR. Arterial stiffness in CKD: a review. AmJ Kidney Dis. 2019;73(2):240-7.

  6. Harris TB, Launer LJ, Eiriksdottir G, KjartanssonO, Jonsson PV, Sigurdsson G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study:multidisciplinary applied phenomics. Am J Epidemiol.2007;165(9):1076-87.

  7. Sedaghat S, Mattace-Raso FU, Hoorn EJ, UitterlindenAG, Hofman A, Ikram MA, et al. Arterial stiffnessand decline in kidney function. Clin J Am Soc Nephrol.2015;10(12):2190-7.

  8. Huang N, Foster MC, Mitchell GF, AndresdottirMB, Eiriksdottir G, Gudmundsdottir H, et al. Aorticstiffness and change in glomerular filtration rate andalbuminuria in older people. Nephrol Dial Transplant.2017;32(4):677-84.

  9. Woodard T, Sigurdsson S, Gotal JD, Torjesen AA, InkerLA, Aspelund T, et al. Mediation analysis of aorticstiffness and renal microvascular function. J Am SocNephrol. 2015;26(5):1181-7.

  10. Prunotto M, Gabbiani G, Pomposiello S, Ghiggeri G,Moll S. The kidney as a target organ in pharmaceuticalresearch. Drug Discov Today. 2011;16(5-6):244-59.

  11. Vivian E, Mannebach C. Therapeutic approaches toslowing the progression of diabetic nephropathy - is lessbest? Drugs Context. 2013;2013:212249.

  12. Franklin SS, Khan SA, Wong ND, Larson MG,Levy D. Is pulse pressure useful in predicting risk forcoronary heart Disease? The Framingham heart study.Circulation. 1999;100(4):354-60.

  13. Franklin SS. Pulse pressure as a risk factor. Clin ExpHypertens. 2004;26(7-8):645-52.

  14. Selvaraj S, Steg PG, Elbez Y, Sorbets E,Feldman LJ, Eagle KA, et al. Pulse pressure andrisk for cardiovascular events in patients withatherothrombosis: from the REACH Registry. J AmColl Cardiol. 2016;67(4):392-403.

  15. Fernández-Fresnedo G, Rodrigo E, de Francisco AL,de Castro SS, Castañeda O, Arias M. Role of pulsepressure on cardiovascular risk in chronic kidney diseasepatients. J Am Soc Nephrol. 2006;17(12 Suppl 3):S246-9.

  16. Arulkmaran N, Diwakar R. Tahir Z, MohamedM, Kaski JC, Banerjee D. Pulse pressure andprogression on chronic kidney disease. J Nephrol.2010;23(2):189-93.

  17. O’Hare AM, Glidden DV, Fox CS, Hsu CY. Highprevalence of peripheral arterial disease in persons withrenal insufficiency: results from the National Health andNutrition Examination Survey 1999-2000. Circulation.2004;109(3):320-3.

  18. Wattanakit K, Folsom AR, Selvin E, Coresh J,Hirsch AT, Weatherley BD. Kidney function andrisk of peripheral arterial disease: results from theAtherosclerosis Risk in Communities (ARIC) Study. JAm Soc Nephrol. 2007;18(2):629-36.

  19. Mostaza JM, Suarez C, Manzano L, Cairols M, García-Iglesias F, Sanchez-Alvarez J, et al. Relationship betweenankle-brachial index and chronic kidney disease inhypertensive patients with no known cardiovasculardisease. J Am Soc Nephrol. 2006;17(12 Suppl 3):S201-5.

  20. Cheung A, Sarnak M. Yan G, Dwyer JT, HeykaRJ, Rocco MV, Teehan BP, Levey AS. Atheroscleroticcardiovascular disease risk in chronic hemodialysispatients. Kidney Int. 2000;58(1):353-62

  21. Chen FA, Yang CY, Yang WC, Chen JY, NgYY, Li SY, et al. Ankle-brachial index is a powerfulpredictor of renal outcome and cardiovascularevents in patients with chronic kidney disease.ScientificWorldJournal. 2012;2012:238494.

  22. Corretti MC, Anderson TJ, Benjamin EJ, CelermajerD, Charbonneau F, Creager MA, et al. Guidelines forthe ultrasound assessment of endothelial-dependentflow-mediated vasodilation of the brachial artery: Areport of the International Brachial Artery ReactivityTask Force. J Am Coll Cardiol. 2002;39(2):257-65.

  23. Charakida M, Masi S, Lüscher TF, KasteleinJJ, Deanfield JE. Assessment of atherosclerosis:the role of flow-mediated dilatation. Eur Heart J.2010;31(23):2854-61.

  24. Fliser D, Wiecek A, Suleymanlar G, Ortiz A, MassyZ, Lindholm B, et al.; for EUropean REnal andCArdiovascular Medicine working group of theEuropean Renal Association-European Dialysis andTransplant Association (ERA-EDTA). The dysfunctionalendothelium in CKD and in cardiovascular disease:mapping the origin(s) of cardiovascular problemsin CKD and of kidney disease in cardiovascularconditions for a research agenda. Kidney Int Suppl.2011;1(1):6-9.

  25. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, CaglarK, Eyileten T, et al. Serum visfatin concentration andendothelial dysfunction in chronic kidney disease.Nephrol Dial Transplant. 2008;23(3):959-65.

  26. Touboul PJ, Vicaut E, Labreuche J, Belliard JP,Cohen S, Kownator S, et al. Correlation between theFramingham risk score and intima media thickness: theParoi Artérielle et Risque Cardio-vasculaire (PARC)study. Atherosclerosis. 2007;192(2):363-9.

  27. Nambi V, Chambless L, Folsom AR, He M, Hu Y,Mosley T, et al. Carotid intima-media thickness andpresence or absence of plaque improves prediction ofcoronary heart disease risk: the ARIC (AtherosclerosisRisk In Communities) study. J Am Coll Cardiol.2010;55(15):1600-7.

  28. Lorenz MW, Markus HS, Bots ML, Rosvall M, SitzerM. Prediction of clinical cardiovascular events withcarotid intima-media thickness: a systematic review andmeta-analysis. Circulation. 2007;115(4):459-67.

  29. Shoji T, Emoto M, Tabata T, Kimoto E, ShinoharaK, Maekawa K, et al. Advanced atherosclerosis inpredialysis patients with chronic renal failure. KidneyInt. 2002;61(6):2187-92.

  30. Park TH. Evaluation of Carotid Plaque UsingUltrasound Imaging. J Cardiovasc Ultrasound.2016;24(2):91-5.

  31. Palanca A, Castelblanco E, Perpiñán H, Betriu À,Soldevila B, Valdivielso JM, et al. Prevalence andprogression of subclinical atherosclerosis in patientswith chronic kidney disease and diabetes. Atherosclerosis.2018;276:50-57.

  32. Lindner A, Charra B, Sherrard DJ, Scribner BH.Accelerated atherosclerosis in prolonged maintenancehemodialysis. N Engl J Med. 1974;290(13):697-701.

  33. Olechnowicz-Tietz S, Gluba A, Paradowska A,Banach M, Rysz J. The risk of atherosclerosis inpatients with chronic kidney disease. Int Urol Nephrol.2013;45(6):1605-12.

  34. Palanca A, Castelblanco E, Betriu A, PerpiñánH, Soldevila B, Valdivielso JM, et al. Subclinicalatherosclerosis burden predicts cardiovascular events inindividuals with diabetes and chronic kidney disease.Cardiovasc Diabetol. 2019;18:93.

  35. Calogero E, Fabiani I, Pugliese NR, Santini V,Ghiadoni L, Di Stefano R, et al. Three-dimensionalechographic evaluation of carotid artery disease. JCardiovasc Echogr. 2018;28(4):218-27.

  36. Go A, Chertow G. Fan D, McCulloch CE, HsuCY. Chronic kidney disease and the risk of death,cardiovascular events and hospitalizations. N Engl JMed. 2004;351(13):1296-305.

  37. Bos D, Leening M, Kavousi M, Hofman A, FrancoOH, van der Lugt A, et al. Comparison of atheroscleroticcalcification in major vessels beds on the risk of all-causeand cause-specific mortality: The Rotterdam study. CircCardiovasc Imaging. 2015;8(12):e003843.

  38. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM,Lorriaux C, et al. Peripheral vascular calcificationin long-haemodialysis patients: associated factorsand survival consequences. Nephrol Dial Transplant.2009;24(3):948-55.

  39. Blaha MJ, Budoff MJ, Tota-Maharaj R, Dardari ZA,Wong ND, Kronmal RA, et al. Improving the CACScore by Addition of Regional Measures of CalciumDistribution: Multi-Ethnic Study of Atherosclerosis.JACC Cardiovasc Imaging. 2016;9(12):1407-1416.

  40. Ferencik M, Pencina KM, Liu T, Ghemigian K,Baltrusaitis K, Massaro JM, et al. Coronary ArteryCalcium Distribution Is an Independent Predictor ofIncident Major Coronary Heart Disease Events: ResultsFrom the Framingham Heart Study. Circ CardiovascImaging. 2017;10(10):e006592.

  41. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N,Higa N, Touma T, et al. Impact of high coronaryartery calcification score (CACS) on survival inpatients on chronic hemodialysis. Clin Exp Nephrol.20004;8(1):54-8.

  42. Nichols WW, O’Rourke MF, McDonald DA. Bloodflow in arteries: theoretic, experimental, and clinicalprinciples. 6th ed. London: Hodder Arnold, 2011. 755 p.

  43. Van Bortel LM, Laurent S, Boutouyrie P, ChowienczykP, Cruickshank JK, De Backer T, et al. Expert consensusdocument on the measurement of aortic stiffness indaily practice using carotid-femoral pulse wave velocity.J Hypertens. 2012;30(3):445-8.

  44. Zócalo Y, Bia D. Presión aórtica central y parámetrosclínicos derivados de la onda del pulso: evaluaciónno invasiva en la práctica clínica. Rev Urug Cardiol.2014;29:215-30.

  45. Chirinos JA, Segers P, Hughes T, Townsend R. Largearterystiffness in health and disease: JACC state-of-theartreview. J Am Coll Cardiol. 2019;74(9):1237-63.

  46. Reference Values for Arterial Stiffness’ Collaboration.Determinants of pulse wave velocity in healthy peopleand in the presence of cardiovascular risk factors:‘establishing normal and reference values’. Eur Heart J.2010;31(19):2338-50.

  47. Williams B, Mancia G, Spiering W, Agabiti Rosei E,Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelinesfor the management of arterial hypertension. Eur HeartJ. 2018;39(33):3021-104.

  48. Vlachopoulos C, Aznaouridis K, Stefanadis C.Prediction of cardiovascular events and all-causemortality with arterial stiffness: a systematic review andmeta-analysis. J Am Coll Cardiol. 2010;55(13):1318-27.

  49. Ben-Shlomo Y, Spears M, Boustred C, May M,Anderson SG, Benjamin EJ, et al. Aortic pulse wavevelocity improves cardiovascular event prediction: anindividual participant meta-analysis of prospectiveobservational data from 17,635 subjects. J Am CollCardiol. 2014;63(7):636-646.

  50. Townsend RR, Anderson AH, Chirinos JA, FeldmanHI, Grunwald JE, Nessel L, et al. Association of pulsewave velocity with chronic kidney disease progressionand mortality: findings from the CRIC Study(Chronic Renal Insufficiency Cohort). Hypertension.2018;71(6):1101-7.

  51. Jablonski KL, Decker E, Perrenoud L, Kendrick J,Chonchol M, Seals DR, et al. Assessment of vascularfunction in patients with chronic kidney disease. J VisExp. 2014;(88):51478.

  52. Lioufas N, Hawley CM, Cameron JD, ToussaintND. Chronic kidney disease and pulse wave velocity:a narrative review. Int J Hypertens. 2019;2019:9189362.

  53. Blacher J, Guerin AP, Pannier B, Marchais SJ,Safar ME, London GM. Impact of aortic stiffnesson survival in end-stage renal disease. Circulation.1999;99(18):2434-9.

  54. Guerin AP, Blacher J, Pannier B, Marchais SJ, SafarME, London GM. Impact of aortic stiffness attenuationon survival of patients in end-stage renal failure.Circulation. 2001;103(7):987-92.

  55. Pannier B, Guérin AP, Marchais SJ, Safar ME, LondonGM. Stiffness of capacitive and conduit arteries:prognostic significance for end-stage renal diseasepatients. Hypertension. 2005;45(4):592-6.

  56. Shoji T, Emoto M, Shinohara K, Kakiya R, TsujimotoY, Kishimoto H, et al. Diabetes mellitus, aortic stiffness,and cardiovascular mortality in end-stage renal disease.J Am Soc Nephrol. 2001;12(10):2117-24.

  57. Zoungas S, Cameron JD, Kerr PG, Wolfe R, MuskeC, McNeil JJ, et al. Association of carotid intimamedialthickness and indices of arterial stiffness withcardiovascular disease outcomes in CKD. Am J KidneyDis. 2007;50(4):622-30.

  58. McEniery CM, Cockcroft JR, Roman MJ, FranklinSS, Wilkinson IB. Central blood pressure: currentevidence and clinical importance. Eur Heart J.2014;35(26):1719-25.

  59. Sharman JE, Avolio AP, Baulmann J, Benetos A,Blacher J, Blizzard CL, et al. Validation of non-invasivecentral blood pressure devices: ARTERY Society taskforce consensus statement on protocol standardization.Eur Heart J. 2017;38(37):2805-12.

  60. Herbert A, Cruickshank JK, Laurent S, BoutouyrieP; Reference Values for Arterial MeasurementsCollaboration. Establishing reference values for centralblood pressure and its amplification in a general healthypopulation and according to cardiovascular risk factors.Eur Heart J. 2014;35(44):3122-33.

  61. Hashimoto J. Central hemodynamics and targetorgan damage in hypertension. Tohoku J Exp Med.2014;233(1):1-8.

  62. Williams B, Lacy PS, Thurston H, Thom S, HughesA, Cruickshank K, et al. Response to Letters regardingarticle, “Differential impact of blood pressureloweringdrugs on central aortic pressure and clinicaloutcomes: principal results of the Conduit ArteryFunction Evaluation (CAFE) Study”. Circulation.2006;114(15):e540-1.

  63. Ryuzaki M, Morimoto S, Niiyama M, Seki Y, YoshidaN, Oshima Y, et al. The relationships between thedifferences in the central blood pressure and brachialblood pressure and other factors in patients withessential hypertension. Intern Med. 2017;56(6):587-96.

  64. Rahman M, Hsu JY, Desai N, Hsu CY, AndersonAH, Appel LJ, et al. Central blood pressure andcardiovascular outcomes in chronic kidney disease. ClinJ Am Soc Nephrol. 2018;13(4):585-95.

  65. Roman MJ, Devereux RB, Kizer JR, Lee ET, GallowayJM, Ali T, et al. Central pressure more strongly relatesto vascular disease and outcome than does brachialpressure: the Strong Heart Study. Hypertension.2007;50(1):197-203.

  66. Pini R, Cavallini MC, Palmieri V, Marchionni N, DiBari M, Devereux RB, et al. Central but not brachialblood pressure predicts cardiovascular events in anunselected geriatric population: the ICARe DicomanoStudy. J Am Coll Cardiol. 2008;51(25):2432-9.

  67. Safar ME, Blacher J, Pannier B, Guerin AP, MarchaisSJ, Guyonvarc’h PM, et al. Central pulse pressure andmortality in end-stage renal disease. Hypertension.2002;39(3):735-8.




2020     |     www.medigraphic.com